Clinical Trial

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2025 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single arm trial in patients with ≥ 18 years with relapsed and refractory DLBCL. Aim of this study is to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab, gemcitabine, and oxaliplatin with or without polatuzumab vedotin (Pirto-R-GemOx±pola) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) previously treated with covalent BTK inhibitors.
Trial Details
NCT Number NCT07122609
Lead Sponsor Ruijin Hospital
Conditions Relapsed and Refractory DLBCL
Enrollment 22 participants
Start Date 2025-08-05
Primary Completion 2026-08-15 (estimated)
Study Completion 2027-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-08-14